Background

Immune inflammatory diseases (IMIDs) are a group of chronic diseases that affect more than 5% of the world's population. They have a significant impact on the quality of life of many patients and represent a large socio-economic burden. These diseases are extremely complex and heterogeneous and have limited, expensive and often unsuccessful treatment options.

IMIDomics works on the discovery and development of new drugs for the treatment of immune-mediated inflammatory diseases such as: rheumatoid arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, etc. 

The identification of biomarkers that predict disease susceptibility, treatment responses, and prognosis would provide major advances in managing these important diseases.

Solution to the unresolved need

IMIDomics, as an innovative leader in the discovery and application of biomarkers, has new goals to control and cure these inflammatory diseases.

The company creates added value through the combination of one of the world's largest immune-treated inflammatory disease biobanks, extensive clinical expertise, high-throughput genomics, genetic analysis and intellectual property.

IMIDomics has established a precision platform that uses clinical, molecular data and advanced analytical methodology to understand the fundamental mechanisms of immune-mediated inflammatory diseases and thus be able to develop new medicines that are more effective and safer for certain subgroups of patients

The company is a spin-off of the Vall d'Hebron Research Institute (VHIR).

Schedule:

• 2015: Initial investment 700k and transfer of patents.
• 2017: Strategic agreement with Celgene with an investment of more than 2 million dollars.
• 2020: Capital round in series A negotiation.
• 2021: $16.5 million funding round. DNS Capital, Bristol Myers Squibb, The Pritzker Organization and TAO Capital, among other investors.